Oncology Consultations Vol. 5, No. 1 |
|
- Therapeutic Options for ER+/HER2– Breast Cancer
1 AMA PRA Category 1 CreditTM
Expiration date: June 6, 2009
|
Patient Communication: The Surgeon’s Role |
|
- Interpretation of Breast Cancer Biomarkers
- Individualized Benefits and Side Effects of Systemic Therapy
- Promises and Limitations of Targeted Therapy
- Advocacy in Cancer Care and Research
- Learning How to Counsel Our Patients
1 AMA PRA Category 1 CreditTM
Expiration date: June 6, 2009
|
From Genome to Clinic: Translating Discoveries Into Practice |
|
- Targeting Growth Factor Receptors: Current Impact and Future Potential
- Therapeutic Applications of Angiogenesis-Based Therapies
1 AMA PRA Category 1 CreditTM
Expiration date: June 4, 2009
|
Molecular Profiling:Improving Precision in Adjuvant Therapy Decisions for Early-Stage Breast Cancer |
|
- Multigene Assays: A Window Into Breast Cancer Behavior
1 AMA PRA Category 1 CreditTM
Expiration date: June 4, 2009
|
Breast Cancer Journal Club Vol. 5, No. 2 |
|
- Lapatinib/Capecitabine for ErbB2-Positive Advanced Breast Cancer
- Cardiac Safety of Doxorubicin/Cyclophosphamide Followed by Paclitaxel ± Trastuzumab
- Phase II Study of Predictive Biomarker Profiles With Lapatinib in IBC
- Trastuzumab/Tanespimycin in Trastuzumab-Refractory ErbB2-Positive Breast Cancer
1 AMA PRA Category 1 CreditTM
Expiration date: May 6, 2009
|
Case Studies in Breast Cancer Vol. 6, No. 1 |
|
- ErbB TKIs in ErbB2-Positive IBC
1 AMA PRA Category 1 CreditTM
Expiration date: May 5, 2009
|
Controversies in Adjuvant Endocrine Therapy for Breast Cancer |
|
- Adjuvant Endocrine Therapy in 2007
- Optimizing Endocrine Therapy for Patients With Early-Stage Breast Cancer
- Controversies in Extending Adjuvant Therapy Beyond 5 Years
- Should Patients Receiving Adjuvant AIs for Breast Cancer Receive Bisphosphonates?
1 AMA PRA Category 1 CreditTM
Expiration date: April 25, 2009
|
Practical Updates in Breast Cancer |
|
- Adjuvant Chemotherapy for Early-Stage Breast Cancer
2 AMA PRA Category 1 CreditsTM
Expiration date: April 15, 2009
|
Contemporary Trends in Chemotherapy for Advanced/Metastatic Breast Cancer |
|
- Single vs. Combination Therapy: Which Agents and What Clinical Situation?
- Chemotherapy and Biologically Targeted Agents: Synergy and Side-Effect Profile
- LABC as aModel for the Study and Optimization of Chemotherapeutic Regimens
- Protein and Genetic Markers in Deciding Optimal Chemotherapy
1 AMA PRA Category 1 CreditTM
Expiration date: March 10, 2009 |
Clinical Advances in Breast Cancer
Vol. 1 No. 1 |
|
- HER2-Positive Early-Stage Breast Cancer: Decision-Making and Practical Management
- Role of Genomics and Emerging Novel Molecular Diagnostic Tests in the Routine Management of Early-Stage Breast Cancer
1 AMA PRA Category 1 CreditTM
Expiration date: March 03, 2009 |
Clinical Breast Cancer
Vol. 8 Suppl. 1 |
|
- Advances in Chemotherapy and Supportive Therapy for Breast Cancer
- Dose-Dense Therapy in the Treatment of Early-Stage Breast Cancer: An Overview of the Data
- Management of Febrile Neutropenia and Cardiac Toxicity in the Adjuvant Treatment of Breast Cancer
- Managing Bone Loss in Women with Early-Stage Breast Cancer Receiving Aromatase Inhibitors
- New Strategies for the Treatment of Metastatic Bone Disease
1.5 AMA PRA Category 1 CreditTM
Expiration date: March 03, 2009 |
Oncology Consultations
Vol. 4, No. 12 |
|
- Treatment of HER2-Positive/Hormone Receptor–Positive Metastatic Breast Cancer With Endocrine Therapy Plus HER2-Targeted Therapy
1 AMA PRA Category 1 CreditTM
Expiration date: March 03, 2009 |
Case Studies in Breast Cancer
Vol. 5, No. 10 |
|
- Treatment of a Patient With Relapsed ErbB2-Positive Metastatic Breast Cancer With Lapatinib
1 AMA PRA Category 1 CreditTM
Expiration date: December 26, 2009 |
Emerging
Biologic Approaches for the Treatment of Breast Cancer
|
|
- Who Needs Adjuvant HER2-Targeted Therapy
- Novel Therapies
for HER2-Positive Breast Cancer
- Confusion on the
HER2 Front: Not All Decisions Are Black and White
- Inhibiting the Tumor Microenvironment
- Targeting Oncogene Addiction in
Breast Cancer: Key Pathways and Novel Targets
1 AMA PRA Category 1 CreditTM
Expiration date: December 22, 2008 |
Biologic Therapy of Breast Cancer Vol. 8, No. 4 |
|
- Rationale and Clinical Data for Combined Inhibition of HER2 and Vascular Endothelial Growth Factor Receptor Pathways in Breast Cancer
- Genomic Rearrangements in Breast Cancer: Clinical Implications
- Putative Breast Cancer Stem Cells as Therapeutic Targets
1 AMA PRA Category 1 CreditTM
Expiration date: December 14, 2008 |
Controversies in Biologic Therapy of Breast Cancer |
|
- Controversies in Adjuvant Therapy: Treatment Options for Patients With Node-Negative, HER2-Positive, Early-Stage Breast Cancer
- Controversies in Metastatic Breast Cancer: Treatment Options for HER2-Positive Disease
- Controversies in Metastatic Breast Cancer: Treatment Options for HER2-Negative Disease
1 AMA PRA Category 1 CreditTM
Expiration date: December 14, 2008 |
Targeted
Therapies in Oncology Vol. 6, No. 1 |
|
- Novel Strategies for Treating Ovarian Cancer
- Emerging Monoclonal Antibodies for the
Treatment of HER2- Positive Breast Cancer
1 AMA PRA Category 1 CreditTM
Expiration date: December 7, 2008 |
Beyond
Taxanes: New Chemotherapeutic Options for Patients With
Refractory Metastatic Breast Cancer |
|
- Multidrug Resistance and Microtubule-Inhibiting
Agents: Underlying Mechanisms and Predictive Factors
- Epothilones and Other Novel Microtubule-Targeting
Agents in Clinical Development
- Practical Management of Resistant/Refractory Metastatic Breast Cancer
1 AMA PRA Category 1 CreditTM
Expiration date: December 7, 2008 |
Utilizing Genomic Tools for Decision Making in Hormone Receptor–Positive Early-Stage Breast Cancer |
|
- Genomic Tools for Decision Making in Early-Stage Breast Cancer
1 AMA PRA Category 1 CreditTM
Expiration date: November 30, 2008 |
Advances in Microtubule-Targeting Strategies in Breast Cancer |
|
- History of Microtubule-Targeted Agents in Breast Cancer as a Model for Drug Development
- Novel Microtubule-Targeting Agents in Clinical Development in Breast Cancer
1 AMA PRA Category 1 CreditTM
Expiration date: November 20, 2008 |
Emerging Pathways With Therapeutic Potential in Cancer |
|
- Targeting Signaling Pathways to Inhibit Cancer Growth
- Targeting the MAP/MEK and PI3K/Akt Pathways
- Novel Small-Molecular Inhibitors Targeting VEGFR in Breast Cancer
- Vaccines in Lung Cancer
- Novel Immunologic Targets in Metastatic Melanoma
- Combining Targeted Agents to Improve Therapeutic Efficacy
1 AMA PRA Category 1 CreditTM
Expiration date: November 20, 2008 |
The Evolving Utility of Biologic Therapy in Breast Cancer |
|
- Optimizing Adjuvant Therapy With HER2-Targeted MoAbs
- Clinical Utility and Future Prospects of Small-Molecule HER TKIs
- Breast Cancer Resistant to HER2-Targeted Therapies
- Clinical Utility and the Future of Angiogenesis Inhibitor Therapy
- Emerging Applications of IGF-1R–Targeted Therapy
1 AMA PRA Category 1 CreditTM
Expiration date: November 20, 2008 |
New Paradigms in the Biologic Therapy of Breast Cancer: Translating Advances in Molecular Biology Into Improved Patient Outcomes |
|
- HER2-Targeted Therapy in Early-Stage Breast Cancer
- Emerging Targeting Agents in HER2+ Breast Cancer
- Angiogenesis Inhibition in Advanced Breast Cancer
- Multiplying the Benefits: Novel Combinations of Targeted Agents
- c-Myc Amplification and Other Genetic Alterations in HER2+ Breast Cancer
1 AMA PRA Category 1 CreditTM
Expiration date: November 20, 2008 |
Oncology Briefings Vol. 5, No. 8 |
|
- Paclitaxel Formulations in MBC
1 AMA PRA Category 1 CreditTM
Expiration date: November 20, 2008 |
Oncology Consultations Vol. 4, No.9 |
|
- Treatment of a Premenopausal Patient With HR-Positive/Node-Negative Breast Cancer With Adjuvant Therapy
1 AMA PRA Category 1 CreditTM
Expiration date: November 20, 2008 |
Clinical Breast Cancer Vol. 7, Suppl. 1 |
|
- Evolving Strategies in the Maintenance of Bone Health in Breast Cancer
1.5 AMA PRA Category 1 CreditsTM
Expiration date: October 31, 2008 |
Oncology Consultations Vol. 4, No. 7 |
|
- Adjuvant Chemotherapy Plus HER2-Targeted Therapy in HER2-Positive LABC
1 AMA PRA Category 1 CreditTM
Expiration date: October 31, 2008 |
Tailoring ErbB-Directed Therapies for Optimized Care of Breast Cancer Patients |
|
- Structural Basis of ErbB Signaling and ErbB-Targeted Therapies
- Adjuvant/Neoadjuvant Strategies for Targeting ErbB2-Positive Early-Stage Breast Cancer
- Targeted Therapy Options for ErbB2-Positive MBC
- Downstream Modulators of ErbB2 Activity
- Relationship Between ErbB and ER Signaling Pathways
1 AMA PRA Category 1 CreditTM
Expiration date: September 30, 2008 |
Biological Therapy of Breast Cancer Vol. 8, No. 3 |
|
- Increasing the Therapeutic Index of Traditional Chemotherapeutics
- Role of the Tumor Stroma in Breast Cancer and Treatment
- Immune-Mediated Antitumor Effects With Antibody Therapy
1 AMA PRA Category 1 CreditTM
Expiration date: August 31, 2008 |
Cancer Conference Highlights Vol. 9, No. 8 |
|
- Adjuvant Trastuzumab
- Biomarkers Predictive of Response and Toxicity Associated With Trastuzumab
- Novel Developments in Small-Molecule HER2 Inhibitors
- Novel MoAb-Based Approaches in MBC
- Growth Factors and Their Inhibitor
1 AMA PRA Category 1 CreditTM
Expiration date: August 31, 2008 |
Cancer Abstracts & Summaries Vol. 8, No. 5 |
|
- Adjuvant Chemotherapy With or Without Trastuzumab in HER2-Positive Breast Cancer
- First-line Paclitaxel/Lapatinib in MBC
- Phase II Trial of First-line Capecitabine/Bevacizumab in MBC
- Phase II Trial of First-line Docetaxel With or Without Axitinib in MBC
- Phase II Trial of Pertuzumab/Trastuzumab in HER2-Positive MBC
1 AMA PRA Category 1 CreditTM
Expiration date: August 31, 2008 |
| Innovations in Breast Cancer: Novel Strategies for Targeting Microtubules
|
|
- Novel Microtubule-Targeting Agents in MBC
- Epothilones and Other Novel Microtubule-Targeting Agents in MBC
1 AMA PRA Category 1 CreditTM
Expiration date: August 31, 2008 |
Oncology Consultations Vol. 4, No. 4 |
|
- Treatment of a Patient With ErbB2-Positive MBC With a Taxane/Platinum/ErbB2-Targeted Regimen
1 AMA PRA Category 1 CreditTM
Expiration date: July 31, 2008 |
Case Studies in Breast Cancer Vol. 5, No. 6 |
|
- ErbB2-Targeted Therapy in a Patient With Heavily Pretreated Recurrent Inflammatory Breast Cancer
1 AMA PRA Category 1 CreditTM
Expiration date: July 31, 2008 |
| |
